Int J Stomatol

Inter J Stomatol ›› 2018, Vol. 45 ›› Issue (1): 36-41.doi: 10.7518/gjkq.2018.01.007

• Original Articles • Previous Articles     Next Articles

Research progress on multiple endocrine neoplasia type 2

Zhang Meihua1, Hu Ying2, Sun Zheng3   

  1. 1. Dept. of Stomatology, The Fourth Affiliated Hospital of Inner Mongolia Medical University, Baotou 014030, China
    2. Institute of Dental Research, Beijing Stomatological Hospital & School of Stomatology, Capital Medical University, Beijing 100050, China
    3. Dept. of Oral Medicine, Beijing Stomatological Hospital & School of Stomatology, Capital Medical University, Beijing 100050, China
  • Received:2017-04-07 Revised:2017-10-12 Online:2018-01-01 Published:2018-01-01

RichHTML

4

PDF (PC)

643

Abstract:

Multiple endocrine neoplasia type 2 (MEN2) is a rare autosomal dominant disease. This condition can be classified into three types, including MEN2A, MEN2B, and familial medullary thyroid carcinoma (MTC). Primary clinical manifestations of this type of neoplasia include the following: MTC, pheochromocytoma, hyperparathyroidism, Hirschsprung’s disease, bone and facial dysplasia, and multiple nerve fibroma of oral mucosa. MTC contributes mainly to early morbidity and high metastasis rate. Patients with MEN2B are prompted to consult with a dentist primarily due to occurrence of multiple mucosa neuroma. Missense mutations in RET gene result in MEN2. RET is located on chromosome 10. Mutations in genotypes of RET genes correlate with phenotype mutations, including age of onset and degree of malignancy. Clinical experiments determined operation time and plan according to genotype. Gene mutations induces changes in RET gene activities, resulting in changes in intra and extracellular signaling pathways. This paper summarizes research progress on clinical and molecular basis, mechanism of RET gene structure and function changes, and MEN2 diagnosis and treatments.

Key words: multiple endocrine neoplasia type 2, medullary thyroid carcinoma, pheochromocytoma, Marfan signs, multiple mucosa neuroma

CLC Number: 

  • R739.8

TrendMD: 
[1]Thakker RV. Multiple endocrine neoplasia type 1 (MEN1)[J]. Best Pract Res Clin Endocrinol Metab, 2010, 24(3):355-370.
[2]Thakker RV. Multiple endocrine neoplasia—synd-romes of the twentieth century[J]. J Clin Endocrinol Metab, 1998, 83(8):2617-2620.
[3]Trump D, Farren B, Wooding C, et al. Clinical stu-dies of multiple endocrine neoplasia type 1 (MEN1) [J]. QJM, 1996, 89(9):653-669.
[4]Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4)[J]. Mol Cell Endocrinol, 2014, 386(1/2):2-15.
[5]Moline J, Eng C. Multiple endocrine neoplasia type 2: an overview[J]. Genet Med, 2011, 13(9):755-764.
[6]Krampitz GW, Norton JA. RET gene mutations (ge-notype and phenotype) of multiple endocrine neo-plasia type 2 and familial medullary thyroid car-cinoma[J]. Cancer, 2014, 120(13):1920-1931.
[7]Kloos RT, Eng C, Evans DB, et al. Medullary thy-roid cancer: management guidelines of the American Thyroid Association[J]. Thyroid, 2009, 19(6):565- 612.
[8]Abraham DT, Low TH, Messina M, et al. Medullary thyroid carcinoma: long-term outcomes of surgical treatment[J]. Ann Surg Oncol, 2011, 18(1):219-225.
[9]Diaz RE, Wohllk N. Multiple endocrine neoplasia: the Chilean experience[J]. Clinics (Sao Paulo), 2012, 67(Suppl 1):7-11.
[10]Brauckhoff M, Machens A, Hess S, et al. Premoni-tory symptoms preceding metastatic medullary thy-roid cancer in MEN 2B: an exploratory analysis[J]. Surgery, 2008, 144(6):1044-1053.
[11]Wohllk N, Schweizer H, Erlic Z, et al. Multiple en-docrine neoplasia type 2[J]. Best Pract Res Clin En-docrinol Metab, 2010, 24(3):371-387.
[12]Jasim S, Ying AK, Waguespack SG, et al. Multiple endocrine neoplasia type 2B with a RET proto-onco-gene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation[J]. Thyroid, 2011, 21(2):189- 192.
[13]Raue F. German medullary thyroid carcinoma/mu-ltiple endocrine neoplasia registry. German MTC/MEN study group. Medullary thyroid carcinoma/multiple endocrine neoplasia type 2[J]. Langenbecks Arch Surg, 1998, 383(5):334-336.
[14]Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pa-thologic predictors of survival in 1252 cases[J]. Can-cer, 2006, 107(9):2134-2142.
[15]Casanova S, Rosenberg-Bourgin M, Farkas D, et al. Phaeochromocytoma in multiple endocrine neoplasia type 2A: survey of 100 cases[J]. Clin Endocrinol (Oxf), 1993, 38(5):531-537.
[16]Modigliani E, Vasen HM, Raue K, et al. Pheochro-mocytoma in multiple endocrine neoplasia type 2: European study. The Euromen study group[J]. J Intern Med, 1995, 238(4):363-367.
[17]Prys-Roberts C. Phaeochromocytoma—recent pro-gress in its management[J]. Br J Anaesth, 2000, 85 (1):44-57.
[18]Martucciello G, Lerone M, Bricco L, et al. Multiple endocrine neoplasias type 2B and RET proto-onco-gene[J]. Ital J Pediatr, 2012, 38:9.
[19]Camacho CP, Hoff AO, Lindsey SC, et al. Early diagnosis of multiple endocrine neoplasia type 2B: a challenge for physicians[J]. Arq Bras Endocrinol Metabol, 2008, 52(8):1393-1398.
[20]Morrison PJ, Nevin NC. Multiple endocrine neo-plasia type 2B (mucosal neuroma syndrome, Wagen-mann-Froboese syndrome)[J]. J Med Genet, 1996, 33(9):779-782.
[21]Sallai A, Hosszú E, Gergics P, et al. Orolabial signs are important clues for diagnosis of the rare endo-crine syndrome MEN 2B. Presentation of two unre-lated cases[J]. Eur J Pediatr, 2008, 167(4):441-446.
[22]Wray CJ, Rich TA, Waguespack SG, et al. Failure to recognize multiple endocrine neoplasia 2B: more common than we think[J]. Ann Surg Oncol, 2008, 15(1):293-301.
[23]Lee NC, Norton JA. Multiple endocrine neoplasia type 2B—genetic basis and clinical expression[J]. Surg Oncol, 2000, 9(3):111-118.
[24]Lee MJ, Chung KH, Park JS, et al. Multiple endocrine neoplasia type 2B: early diagnosis by multiple mu-cosal neuroma and its DNA analysis[J]. Ann Dermatol, 2010, 22(4):452-455.
[25]Raue F, Frank-Raue K. Update multiple endocrine neoplasia type 2[J]. Fam Cancer, 2010, 9(3):449- 457.
[26]Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2[J]. J Clin Endocrinol Metab, 2001, 86(12):5658- 5671.
[27]Engiz O, Ocal G, Siklar Z, et al. Early prophylactic thyroidectomy for RET mutation-positive MEN 2B [J]. Pediatr Int, 2009, 51(4):590-593.
[28]Collins JM, Chaudhry SI, Gill DS, et al. Multiple endocrine neoplasia in an orthodontic patient: in-terprofessional diagnostic and treatment implications [J]. J Am Dent Assoc, 2012, 143(10):1093-1098.
[29]Burzynski GM, Nolte IM, Bronda A, et al. Identi-fying candidate Hirschsprung disease-associated RET variants[J]. Am J Hum Genet, 2005, 76(5):850- 858.
[30]Sotos JG. Abraham Lincoln’s marfanoid mother: the earliest known case of multiple endocrine neoplasia type 2B[J]. Clin Dysmorphol, 2012, 21(3):131-136.
[31]Aung PP, Ballester LY, Abdullaev Z, et al. ER/PR positive epidermotropic primary cutaneous eccrine carcinoma as a cutaneous manifestation of MEN 2B[J]. J Am Acad Dermatol, 2013, 69(6):e310-e312.
[32]Pasini B, Hofstra RM, Yin L, et al. The physical map of the human RET proto-oncogene[J]. Oncogene, 1995, 11(9):1737-1743.
[33]Moore SW, Zaahl MG. Multiple endocrine neoplasia syndromes, children, Hirschsprung’s disease and RET[J]. Pediatr Surg Int, 2008, 24(5):521-530.
[34]Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer[J]. Cyto-kine Growth Factor Rev, 2005, 16(4/5):441-467.
[35]Wells SA Jr, Asa SL, Dralle H, et al. Revised Ame-rican Thyroid Association guidelines for the mana-gement of medullary thyroid carcinoma[J]. Thyroid, 2015, 25(6):567-610.
[36]Raue F, Rondot S, Schulze E, et al. Clinical utility gene card for: multiple endocrine neoplasia type 2 [J]. Eur J Hum Genet, 2012, 20(1). doi:10.1038/ejhg.2011.142.
[37]Yadav K, Bakshi G, Prakash G, et al. Simultaneous bilateral laparoscopic adrenalectomy for pheochro-mocytoma in multiple endocrine neoplasia (MEN) syndrome: case report with review literature[J]. Int J Surg Case Rep, 2014, 5(8):487-490.
[1] Jiang Han,Shen Yingqiang,Chen Qianming. Experimental study of muscarinic receptors on the biological behavior of oral squamous cell carcinoma through Yes related protein signal [J]. Int J Stomatol, 2022, 49(2): 138-143.
[2] Jiang Yulei,Xia Bin,Rao Nanquan,Yang Hefeng,Xu Biao. Exosomes mediate the malignant progression of oral squamous cell carcinoma and its application in diagnosis and treatment [J]. Int J Stomatol, 2021, 48(6): 711-717.
[3] Qian Ying,Gong Jiaxing,Yu Mengfei,Liu Yu,Wei Dong,Zhu Ziyu,Lu Kejie,Wang Huiming. Diagnosis and treatment of ameloblastoma from molecular biology perspective [J]. Int J Stomatol, 2021, 48(5): 570-578.
[4] Wang Yue,Ji Yiming,Wang Xiaoyi,Zhang Lingnan,Sun Legang. Unique biological behavior and treatment of the human papilloma virus 16-related oropharyngeal squamous cell carcinoma [J]. Int J Stomatol, 2021, 48(4): 450-458.
[5] Shen Jie,He Di,Liu Yanming. Research progress on the functional surgery of benign submandibular gland tumors [J]. Int J Stomatol, 2021, 48(2): 230-237.
[6] Wei Binbin,Hu Huiwei,Liu Yujuan,Sun Zhe,Yi Yuli. Meta-analysis and GRADE evaluation of the intervention effects of using amifostine before radiotherapy on xerostomia in patients with head and neck cancer [J]. Int J Stomatol, 2020, 47(5): 547-556.
[7] Kong Lixin,Ren Biao,Cheng Lei. Research progress on regulation of cyclooxygenase-2/prostaglandin E2 pathway on oral cancer [J]. Int J Stomatol, 2020, 47(4): 431-438.
[8] Hao Fu,Ning Yi,Sun Rui,Zheng Xiaoxu. Expression and potential clinical significance of Transformer 2β in oral squamous cell carcinoma [J]. Int J Stomatol, 2020, 47(2): 159-165.
[9] Chen Hongli,Yang Jing,Yin Gang,Li Haoyuan,Qiao Yan. Expression of zinc finger protein 32 in oral squamous cell carcinoma and its effect on oral squamous cell carcinoma stem cells [J]. Int J Stomatol, 2019, 46(6): 631-639.
[10] Hao Fu,Sun Rui. Research progress on second primary carcinoma of head and neck squamous cell carcinoma [J]. Int J Stomatol, 2019, 46(5): 585-592.
[11] Yuanyuan Li,Bin Cheng,Yun Wang. Effects of long non-coding RNA lnc-p26090 on the glycolysis and proliferation in oral squamous cell carcinoma [J]. Inter J Stomatol, 2018, 45(6): 628-634.
[12] Yiting Wang,Yongwen He. Advances in long non-coding RNA regulation of epithelial-mesenchymal transition in oral squamous cancer [J]. Inter J Stomatol, 2018, 45(6): 635-639.
[13] Chuan Fang,Yadong Li. Investigative progresses of microRNA in oral squamous cell carcinoma [J]. Inter J Stomatol, 2018, 45(6): 646-651.
[14] Yu Xinle, Zheng Jun, Xu Jiang, Zeng Yan. Level of N-α-acetyltransferase 10 in saliva and serum of patients with oral squamous cell carcinoma and its clinical significance [J]. Inter J Stomatol, 2018, 45(4): 391-395.
[15] Zhang Qian, Yang Xudong. Research progress on the effectiveness assessment of decompression on large jaw cystic lesions [J]. Inter J Stomatol, 2017, 44(4): 493-496.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[2] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[3] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[4] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[5] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[6] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[7] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[8] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[9] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[10] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .